Polycystic Ovarian Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease.

The Polycystic ovarian syndrome pipeline market research report provides a comprehensive overview on the therapeutics under development for Polycystic ovary syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic ovary syndrome and features dormant and discontinued projects.

Key Targets in the Polycystic Ovary Syndrome Pipeline Drugs Market

In the Polycystic ovary syndrome pipeline drugs market the key targets are Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Androgen Receptor, Corticotropin Releasing Factor Receptor 1, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Nuclear Factor Erythroid 2 Related Factor 2, Patatin Like Phospholipase Domain Containing Protein 2 , and Peroxisome Proliferator Activated Receptor Alpha.

PCOS Drugs Market, by Targets

PCOS Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Polycystic Ovary Syndrome Pipeline Drugs Market

Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator has the highest number of pipeline products followed by Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Corticotropin Releasing Factor Receptor 1 Antagonist, Estrogen Receptor Agonist, Follicle Stimulating Hormone Receptor Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Patatin Like Phospholipase Domain Containing Protein 2 Activator , and Peroxisome Proliferator Activated Receptor Alpha Agonist.

Polycystic Ovary Syndrome Pipeline Drugs Market, by MoA

Polycystic Ovary Syndrome Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Polycystic Ovary Syndrome Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the PCOS pipeline drugs market are Oral, Topical, Subcutaneous, and Vaginal. Oral has the maximum number of pipeline products.

Polycystic Ovary Syndrome Pipeline Drugs Market Analysis, by RoA

Polycystic Ovary Syndrome Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Polycystic Ovary Syndrome Pipeline Drugs Market

The key molecule types in the PCOS pipeline drugs market are Small Molecule, Recombinant Protein, and Cell Therapy.

Polycystic Ovary Syndrome Pipeline Drugs Market, by Molecule Type

Polycystic Ovary Syndrome Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Polycystic Ovary Syndrome Pipeline Drugs Market

The major companies in the Polycystic ovary syndrome pipeline drugs market are EffRx Pharmaceuticals SA, AbbVie Inc, Amaro Therapeutics Inc, Annji Pharmaceutical Co Ltd, Arkay Therapeutics LLC, Bayer AG, Besins Healthcare SA, BioRestorative Therapies Inc, Exeltis Pharmaceuticals Holding SL, Jiangsu Hengrui Medicine Co Ltd, Livzon Pharmaceutical Group Co Ltd, Spruce Biosciences Inc, and Zydus Lifesciences Ltd.

Polycystic Ovary Syndrome Pipeline Drugs Market, by Major Companies

Polycystic Ovary Syndrome Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Polycystic Ovary Syndrome Pipeline Drugs Market Overview

Key Targets Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Androgen Receptor, Corticotropin Releasing Factor Receptor 1, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Nuclear Factor Erythroid 2 Related Factor 2, Patatin Like Phospholipase Domain Containing Protein 2, and Peroxisome Proliferator Activated Receptor Alpha
Key Mechanisms of action Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Androgen Receptor, Corticotropin Releasing Factor Receptor 1 Antagonist, Estrogen Receptor Agonist, Follicle Stimulating Hormone Receptor Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Patatin Like Phospholipase Domain Containing Protein 2 Activator , and Peroxisome Proliferator Activated Receptor Alpha Agonist
Key Routes of Administration Oral, Topical, Subcutaneous, and Vaginal
Key Molecule Types Small Molecule, Recombinant Protein, and Cell Therapy
Major Companies EffRx Pharmaceuticals SA, AbbVie Inc, Amaro Therapeutics Inc, Annji Pharmaceutical Co Ltd, Arkay Therapeutics LLC, Bayer AG, Besins Healthcare SA, BioRestorative Therapies Inc, Exeltis Pharmaceuticals Holding SL, Jiangsu Hengrui Medicine Co Ltd, Livzon Pharmaceutical Group Co Ltd, Spruce Biosciences Inc, and Zydus Lifesciences Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic ovary syndrome
  • The pipeline guide reviews pipeline therapeutics for Polycystic ovary syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic ovary syndrome therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic ovary syndrome therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Polycystic ovary syndrome

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic ovary syndrome
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic ovary syndrome pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Amaro Therapeutics Inc
Annji Pharmaceutical Co Ltd
Arkay Therapeutics LLC
Bayer AG
Besins Healthcare SA
BioRestorative Therapies Inc
EffRx Pharmaceuticals SA
Exeltis Pharmaceuticals Holding SL
Jiangsu Hengrui Medicine Co Ltd
Livzon Pharmaceutical Group Co Ltd
Spruce Biosciences Inc
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycystic Ovarian Syndrome – Overview

Polycystic Ovarian Syndrome – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycystic Ovarian Syndrome – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycystic Ovarian Syndrome – Companies Involved in Therapeutics Development

AbbVie Inc

Amaro Therapeutics Inc

Annji Pharmaceutical Co Ltd

Arkay Therapeutics LLC

Bayer AG

Besins Healthcare SA

BioRestorative Therapies Inc

EffRx Pharmaceuticals SA

Exeltis Pharmaceuticals Holding SL

Jiangsu Hengrui Medicine Co Ltd

Livzon Pharmaceutical Group Co Ltd

Spruce Biosciences Inc

Zydus Lifesciences Ltd

Polycystic Ovarian Syndrome – Drug Profiles

(celecoxib + metformin hydrochloride + valsartan) – Drug Profile

Product Description

Mechanism Of Action

(dienogest + ethinylestradiol) PR – Drug Profile

Product Description

Mechanism Of Action

ALZ-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drug 1 for Polycystic Ovarian Syndrome – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Agonize TAS2R1 for Polycystic Ovarian Syndrome (PCOS) – Drug Profile

Product Description

Mechanism Of Action

elagolix sodium – Drug Profile

Product Description

Mechanism Of Action

History of Events

follitropin alfa biosimilar – Drug Profile

Product Description

Mechanism Of Action

metformin hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

progesterone – Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein to Agonize PEDF for Women’s Health – Drug Profile

Product Description

Mechanism Of Action

saroglitazar – Drug Profile

Product Description

Mechanism Of Action

History of Events

SHR-7280 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ThermoStem – Drug Profile

Product Description

Mechanism Of Action

History of Events

tildacerfont – Drug Profile

Product Description

Mechanism Of Action

History of Events

Polycystic Ovarian Syndrome – Dormant Projects

Polycystic Ovarian Syndrome – Discontinued Products

Polycystic Ovarian Syndrome – Product Development Milestones

Featured News & Press Releases

Sep 10, 2021: Livzon Pharmaceutical Group announcement on obtaining approval notice for clinical trial on a drug

Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome

Oct 01, 2013: EffRx Receives Prestigious EUR

5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Polycystic Ovarian Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Polycystic Ovarian Syndrome – Pipeline by AbbVie Inc, 2022

Polycystic Ovarian Syndrome – Pipeline by Amaro Therapeutics Inc, 2022

Polycystic Ovarian Syndrome – Pipeline by Annji Pharmaceutical Co Ltd, 2022

Polycystic Ovarian Syndrome – Pipeline by Arkay Therapeutics LLC, 2022

Polycystic Ovarian Syndrome – Pipeline by Bayer AG, 2022

Polycystic Ovarian Syndrome – Pipeline by Besins Healthcare SA, 2022

Polycystic Ovarian Syndrome – Pipeline by BioRestorative Therapies Inc, 2022

Polycystic Ovarian Syndrome – Pipeline by EffRx Pharmaceuticals SA, 2022

Polycystic Ovarian Syndrome – Pipeline by Exeltis Pharmaceuticals Holding SL, 2022

Polycystic Ovarian Syndrome – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Polycystic Ovarian Syndrome – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022

Polycystic Ovarian Syndrome – Pipeline by Spruce Biosciences Inc, 2022

Polycystic Ovarian Syndrome – Pipeline by Zydus Lifesciences Ltd, 2022

Polycystic Ovarian Syndrome – Dormant Projects, 2022

Polycystic Ovarian Syndrome – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Polycystic Ovarian Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Polycystic Ovarian Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Polycystic Ovarian Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Polycystic Ovarian Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.